<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Management of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> should focus on decreasing the excess macrovascular disease with which it is associated as well as preventing or minimizing microvascular disease </plain></SENT>
<SENT sid="1" pm="."><plain>Near-normoglycemic control can reduce microvascular disease </plain></SENT>
<SENT sid="2" pm="."><plain>Reducing macrovascular disease requires concomitant management of the <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> (components of the <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> syndrome) associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The first phase of such treatment is to identify the effects that the various drugs to treat the <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> are likely to have on these associated <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Appropriate combinations of antihyperglycemic agents should be selected for specific patients to help achieve good glycemic control and produce beneficial, or at least nondetrimental, effects on cardiovascular risk </plain></SENT>
</text></document>